Patents Represented by Attorney James S. Keddie
  • Patent number: 8027823
    Abstract: A computer-implemented method for viewing experimental data is provided. In certain embodiments the method comprises: a) inputting genomic array data and cytogenetic data into a computer memory; and b) producing a graphical user interface comprising: i) a chromosomal map of the genomic array data comprising a first positional indicator that indicates a position on the chromosomal map; and ii) a cytogenetic map of the cytogenetic data comprising a second positional indicator that indicates a position on the cytogenetic map.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: September 27, 2011
    Assignee: Agilent Technologies, Inc.
    Inventors: Michael T. Barrett, Michael P. Caren
  • Patent number: 7979215
    Abstract: Methods of evaluating candidate CGH probe nucleic acid sequences are provided. Aspects of the methods include providing a candidate CGH probe nucleic acid sequence for a target sequence of a copy number variation (CNV) of a genome. A proximity score is then determined for the candidate CGH probe nucleic acid sequence and employed to evaluate the sequence. Aspects of the invention further include computer programming and systems that include the same which are configured to evaluate candidate CGH probe nucleic acid sequences using a proximity score.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: July 12, 2011
    Assignee: Agilent Technologies, Inc.
    Inventor: Nicholas M. Sampas
  • Patent number: 7970549
    Abstract: The present invention provides an apparatus, system, method and computer program and computer program product for analyzing cellular samples. One embodiment of the apparatus and method provides a multiparameter assay that provides information with respect to cell proliferation, cell cycling and cell death. The multiparameter assay is particularly useful for assessing and screening candidate compounds for anti-cancer utility.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: June 28, 2011
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Susan Catalano, John McLaughlin
  • Patent number: 7872096
    Abstract: The invention provides methods and compositions for production of a cyclic polymer in a cell free system. In general, the methods of the invention involve ligating first and second recombinant intein domains to a linear synthetic polymer to form a compound containing the structure: D1-X(n)-D2, where D1 is a first catalytic domain of an intein; D2 is a second catalytic domain of an intein; where the second catalytic domain has at its N-terminus a first reactive site for the intein; and X(n) is a polymer of a number n of monomer X, where the polymer N-terminus has a second reactive site for the intein. D1-X(n)-D2 compounds autocatalytically cyclize the X(n) polymer to produce a cyclic polymer. The invention finds use in a variety of drug discovery, clinical and therapeutic applications.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: January 18, 2011
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Todd M. Kinsella
  • Patent number: 7745196
    Abstract: The invention provides methods and compositions for identifying modulators, particularly peptide modulators, of cell surface receptor activity. Specifically, the invention provides a cell containing a recombinant nucleic acid encoding a polypeptide modified for intracellular presentation, which cell may further comprise one or both of a recombinant nucleic acid encoding a binding partner for that polypeptide and recombinant nucleic acid encoding a test polypeptide. The subject cell may be a member of a library of cells, and the library may be used in screening methods for identifying test polypeptides (e.g., conformationally restrained polypeptides) having cell surface receptor modulatory activity. The invention finds use in a variety of drug-discovery applications.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: June 29, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Brian Wong, Donald G. Payan
  • Patent number: 7598050
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: October 6, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7566685
    Abstract: The invention relates to methods and compositions utilizing diphtheria toxin for screening purposes. The invention is particularly useful in screening for modulators of IgE synthesis, secretion and switch rearrangement.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: July 28, 2009
    Assignee: Rigel Pharmacauticals, Inc.
    Inventor: Todd M. Kinsella
  • Patent number: 7566765
    Abstract: The present invention provides heterocyclic compounds having a nine-membered ring of three repeating C—C—N subunits covalently bound to each other through amide bonds, and variable side groups linked to a central C of each subunit. Also described herein are cells containing the cyclic compounds, methods of screening those cells to identify a cyclic compound of interest, and libraries of cyclic compounds and their encoding nucleic acids. The subject compounds may be employed in a variety of research and medical applications, including methods of treating a patient for hepatitis C infection.
    Type: Grant
    Filed: January 10, 2005
    Date of Patent: July 28, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Todd M. Kinsella
  • Patent number: 7563585
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: July 21, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7402409
    Abstract: The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods.
    Type: Grant
    Filed: January 23, 2003
    Date of Patent: July 22, 2008
    Assignee: Epitomics, Inc.
    Inventor: Guo-Liang Yu
  • Patent number: 7374894
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL 4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vivo and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: May 20, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7297482
    Abstract: The invention relates to the use of scaffold proteins, particularly green fluorescent protein (GFP), in fusion constructs with random and defined peptides and peptide libraries, to increase the cellular expression levels, decrease the cellular catabolism, increase the conformational stability relative to linear peptides, and to increase the steady state concentrations of the library peptides and peptide library members expressed in cells for the purpose of detecting the presence of the peptides and screening peptide libraries. N-terminal, C-terminal, dual N- and C-terminal and one or more internal fusions are all contemplated. Novel fusions utilizing self-binding peptides to create a conformationally stabilized fusion domain are also contemplated.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: November 20, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: David Anderson, Beau Robert Peelle, Jakob Maria Bogenberger
  • Patent number: 7285383
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: October 23, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 7252952
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: August 7, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Todd M. Kinsella, Todd Pray, Mark K. Bennett
  • Patent number: 7241581
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a c-Myc protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: July 10, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7208289
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: April 24, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7208571
    Abstract: The present invention relates ti methods and compositions utilizing inteins to generated libraries of cyclic peptides in vivo.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: April 24, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Todd M. Kinsella
  • Patent number: 7205130
    Abstract: The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense and antisense orientation, which are useful for the delivery and expression of a combination of genetic effector types to host cells. Methods for producing these libraries through bi-directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: April 17, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Jakob M. Bogenberger
  • Patent number: 7132234
    Abstract: The invention provides methods for identifying an anti-poxviral agents. In many embodiments, the methods involve contacting a poxviral p28 polypeptide with a candidate agent, and determining an effect of the agent on a ubiquitin ligase activity of the p28 polypeptide. The effect of the agent may be determined using a variety of different cell based or biochemical assays, such as polyubiquitylation assays and cell viability assays. The invention also provides methods for modulating poxvirus pathogenicity in a cell, and methods of treating an individual infected with a poxvirus. The subject methods find use in a variety of drug discovery, research and military applications.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: November 7, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Henry H. Lu, Jianing Huang, Donald G. Payan
  • Patent number: 7115860
    Abstract: A source of ions for an analyzer includes a reservoir for containing a liquid, a manifold having a plurality of nozzles, a conduit connecting the reservoir to the manifold and a counter electrode having a potential different between the counter electrode and the nozzles to enable liquid to be ejected from the nozzles in droplets and to enable ions to be ejected from the droplets.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: October 3, 2006
    Inventors: Paul C. Goodley, Jean-Luc Truche